drugset
drugset / Trial / NCT05680818

Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1

NCT05680818 ↗

Phase 3 Active not recruiting 67 enrolled Calcilytix Therapeutics, Inc., a BridgeBio company
RandomizedSequentialOpen-labelTreatment

Summary

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

Timeline

Start
2023-01-06
Primary completion
2025-08-22
Completion
2029-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Encaleret Small molecule — Oral

Indications

autosomal dominant hypocalcemia 1